if this works???, page-6

Dendreon and Prima, although sharing similartities regarding product, will remain quite different in where they stand financially and how they intend bringing their products to market. Dendreon, although suffering setbacks with the US FDA and having to carryout further testing, are in an excellent position to manufacture themselves.

I am confident though, that IF Cvac satisfies the necessary milestones and without unecessary delays/hurdles we COULD see $1.00 to $1.50 and even higher. They are big IF's and COULD's though.

Being first to market with such a treatment will be huge and I am also curious as to Primas intentions to investigate Cvac's potential with other cancers at some stage a long way down tyhe track.